A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

16. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

17. D. Djuric et al., Eur. J. Pharm. Biopharm. 71 (1), 155–160 (2009).

18. A. Debunne, C. Vervaet, and J.P. Remon, Eur. J. Pharm. Biopharm. 54 (3), 343–348 (2002).

19. A. Dukić et al., Eur. J. Pharm. Biopharm. 66 (1), 83–94 (2007).

20. H. Kanbe et al., Int. J. Pharm. 337 (1–2), 56–62 (2007).

21. A. Dukić-Ott et al., Eur. J. Pharm. Biopharm. 70 (1), 302–312 (2008).

22. K.E. Fielden, J.M. Newton, and R.C. Rowe, Int. J. Pharm. 97 (1–3), 79–92 (1993).

23. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

24. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

25. L. Hellén et al., J. Pharm. Tech. Int. 4 (9), 50–60 (1992).

26. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

27. C.C. Ku et al., Drug Dev. Ind. Pharm. 19 (13), 1505–1519 (1993).

28. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

29. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

30. K.A. Mehta et al., J. Control. Release 63 (1–2), 201–211 (2000).

31. S. Galland et al., Chem. Eng. Res. Des. 81 (9), 1237–1242 (2003).

32. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

33. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

34. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

35. C. Vervaet et al., Int. J. Pharm. 107 (1), 29–39 (1994).

36. C. Vervaet and J.P. Remon, Int. J. Pharm. 133 (1–2), 29–37 (1996).

37. R. Dietrich and R. Brausse, Pharm. Ind. 50 (10), 1179–1186 (1988).

38. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2) 205–214 (1997).

39. P.J. Harrison, J.M. Newton, and R.C. Rowe, J. Pharm. Pharmacol. 37 (10), 686–691 (1985).

40. J.F. Pinto, G. Buckton, and J.M. Newton, Int. J. Pharm. 83 (1–3), 187–196 (1992).

41. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

42. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

43. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here